Bristol-Myers Squibb Company / Repertoire Immune Medicines Inc.

Autoimmune diseases (tolerizing vaccine target portfolio, up to 3 indications)

24M US cases/yr · $150.0B Global autoimmune biologic / immunomodulator market (2024) · 1865 BMS-Repertoire deal size (USD MM, $65M upfront + $1.8B milestones)

Disease Overview

Autoimmune and inflammatory disease affects approximately 24 million Americans (NIAID / AARDA), with at least 80 classified disorders ranging from organ-specific (type 1 diabetes, multiple sclerosis, celiac) to systemic (rheumatoid arthritis, SLE, psoriasis). Standard of care is overwhelmingly based on broad immunosuppression — TNF inhibitors (Humira, Enbrel, Remicade), IL-17/23 antagonists (Cosentyx, Stelara, Skyrizi, Tremfya), JAK inhibitors (Xeljanz, Rinvoq, Olumiant), B-cell depleters (Rituxan, Ocrevus) — which control symptoms but do not restore antigen-specific immune tolerance and carry infection, malignancy and reactivation risk. Tolerizing vaccines (antigen-specific immunotherapy) aim to reprogram the immune system to ignore a defined self-antigen without global immunosuppression, by delivering the driver autoantigen in a tolerogenic context (e.g., regulatory T cell induction, deletion of autoreactive clones). Validated target indications span type 1 diabetes (GAD-65, insulin), celiac (gliadin peptides), MS (myelin peptides), pemphigus, and autoimmune hepatitis. The category is pre-commercial — no tolerizing vaccine is approved — but has attracted Big Pharma partnering since 2022 because it offers the possibility of disease remission rather than chronic biologic therapy and could defend against biosimilar erosion of the autoimmune franchise, which BMS and peers face as Humira, Stelara and others lose exclusivity.

Competitive Landscape

The tolerizing-vaccine / antigen-specific immunotherapy field is early but increasingly capitalized. T-cell targeted platforms: Repertoire Immune Medicines DECODE platform (maps the T-cell-MHC-peptide synapse, licensed to BMS April 2024); Cue Biopharma Immuno-STAT platform (partnered with Boehringer for selective T cell modulation). Autoantigen-specific peptide vaccines: ImmunoTolerance / Anokion ANK-700 (celiac, Takeda partnership terminated 2023); TolerCionX / Barinthus Bio (VTP-1000 series). Tolerogenic nanoparticles / microparticles: Cour Pharmaceuticals CNP-101 (celiac, Phase 2b), CNP-104 (primary biliary cholangitis); Anokion KAN-101 (celiac, with Bristol-Myers Squibb rights transferred 2023). Regulatory T cell therapies: Sonoma Biotherapeutics Treg platform (Regeneron partnership), Quell Therapeutics (AstraZeneca partnership for T1D). Adjacent immune-reset approach: CAR-T against CD19 for refractory SLE/MS (Cabaletta, Novartis YTB323). The DECODE-BMS deal is the largest single payment for a T-cell-focused tolerizing vaccine platform to date, validating the Repertoire approach over peptide and nanoparticle-only strategies.